News Stryker Corporation - Largest Companies by Marketcap, Revenue, Net Income and Employees

Stryker stock falls on slower peripheral vascular, hip sales

10.09.2026 12:06

CFO Preston Wells said at a healthcare conference that the company is still working through supply issues in its peripheral vascular business and had fewer hip sales than expected so far this quarter.

Pulmera Appoints Jared Slibeck Chief Commercial Officer

09.09.2026 12:58

Twenty-year industry veteran in surgical navigation and enabling technology joins Pulmera to spearhead commercial adoption of its CBeam™ 3D Imaging Platform, the first C-Arm Native 3D imaging system. 20-Year Stryker Veteran Jared Slibeck Joins Pulmera as Chief Commercial Officer Jared Slibeck has been named Chief Commercial Officer for Pulmera, effective September 1, 2026. Slibeck will lead the company’s commercial strategy and market development as the company brings the CBeam™ 3D Imaging Platf

Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?

04.09.2026 14:27

BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.

Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead

14.08.2026 11:11

Boston Scientific (BSX) stock: EP/WATCHMAN slowdown drives discount valuation. See why itâs a Buyânew launches, insider buying, cost savings.

Stryker (NYSE:SYK): A Quality Investment for Long-Term Investors

14.08.2026 11:01

Stryker (SYK) passes the Caviar Cruise quality screen: strong growth, 36% ROIC, and solid cash conversion. A quality investing standout.

Wolfe Research Downgrades Stryker (SYK)

14.08.2026 07:22

Can Stryker (SYK) Still Look Undervalued After Backlog Recovery?

14.08.2026 03:16

Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Stryker's medical...

Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company

10.08.2026 18:14

Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.

Stryker declares an $0.88 per share quarterly dividend

05.08.2026 13:34

Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer

Stryker (SYK) Q2 2026 Earnings Call Transcript

04.08.2026 00:16

CEO Lobo discusses 9% organic sales growth and margin expansion amid cybersecurity recovery.

Stryker (NYSE:SYK): A Dividend Quality Play Built on Sustainability

03.08.2026 09:40

Discover why Stryker (SYK) passes a dividend screen: sustainable 1.01% yield, 7.89% growth, 38.99% payout, strong profitability. Health rating meets bar.

Solventum (SOLV) Appoints Neil Zieselman As New Chief Accounting Officer

02.08.2026 14:08

Solventum (NYSE:SOLV) has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed current Controller and Chief Accounting Officer Mary Wilcox following her retirement. Zieselman brings experience from Surgery Partners Inc., Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya Inc., and is a licensed CPA. Solventum enters this leadership change with its stock at $85.44 and a value score of 5, which can help...

Is Stryker (SYK) Undervalued As Earnings Trigger A Fresh Valuation Question?

02.08.2026 01:11

Stryker (SYK) is back in focus after its second quarter 2026 earnings, reporting sales of US$6.59b and net income of US$1.28b, alongside a sharp market reaction to the release. See our latest analysis for Stryker. The 1 day share price return of Stryker fell 6.42% on the earnings release, which pulled the year to date share price return down 6.46%, while the 5 year total shareholder return of 30.66% still reflects longer term gains. If Stryker’s move has you reassessing healthcare exposure,...

SYK Q2 Deep Dive: Supply Chain Disruptions Weigh on Growth Outlook Despite Margin Expansion

01.08.2026 03:31

Medical technology company Stryker (NYSE:SYK) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts’ consensus estimates.

Stryker Q2 Earnings Call Highlights

01.08.2026 03:03

Stryker (NYSE:SYK) reported 9% organic sales growth in the second quarter of 2026 and adjusted earnings per share growth of 17.9%, as the medical technology company continued recovering from a cybersecurity incident that disrupted operations earlier in the year. Chair and CEO Kevin Lobo said the co

Stay informed with the top movers within the S&P500 index on Friday.

31.07.2026 19:05

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.

Why Stryker (SYK) Shares Are Plunging Today

31.07.2026 15:23

Shares of medical technology company Stryker (NYSE:SYK) fell 7.3% in the morning session after the company reported second-quarter results that showed revenue that only met Wall Street's expectations and organic sales growth that missed forecasts.